Please Wait...

Expert Biomarker Services For Alzheimer's Disease Research

Alzheimer's Disease (AD), a fatal neurodegenerative disorder characterized by progressive cognitive impairment and memory loss, is the major cause of dementia. The two main neuropathological hallmarks of AD are extracellular amyloid plaques, and neurofibrillary tangles (NTFs), primarily composed of the protein tau.

A biomarker is a characteristic that can be objectively measured and evaluated as an indicator of a normal or pathological process, or as a measure of response to therapy. Application of cerebrospinal fluid-based (CSF) and blood-based biomarkers in clinical research has revolutionized the understanding of AD. Especially, detection of Aβ and tau in CSF has led to crucial advancements in disease detection at its earliest stage (Fig 1).

In general, biomarkers have proven extremely useful throughout the different steps of AD clinical trials: patient inclusion and enrichment, and evaluation of target engagement and clinical efficacy of therapeutic drugs. Changes in CSF and blood-based biomarkers reflect different pathological processes in AD.

Informed Decision-Making. Quality Data. Improved Outcomes.

Bioclinica AD biochemical marker capabilities:

  • Fit-for-Purpose Validation
  • Expertise in Sample Handling
  • Centralized analysis to minimize assay variability
  • Controlled storage of biological samples
  • Established partnership with internationally recognized KOL
  • AD specific Proficiency Testing Program

 

Fluid-based biomarkers can facilitate development of new AD therapies by allowing:

  • Enrichment and stratification of patients
  • Evaluation of target engagment
  • Measurement of disease progression
  • Clinical efficacy and safety assessment of therapeutic drugs

 

Download our AD Biomarker Expertise Sheet

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Attending CBI's IRT conf? Catch 10/27 @bioclinica GSK talk on bens of sponsor controlled #IRT. Here's the core tech… https://t.co/zFiQswIQFb
bioclinica (12 hours ago)
RT @Xtalks: #Cardiovascular Imaging for Monitoring Safety: Visualizing Outcomes @bioclinica https://t.co/5osqBkDFKm
bioclinica (13 hours ago)
Want stellar imaging acquisition & assessment in your #clinicaltrial ? Get tips in @bioclinica 's Tim Crowe's blog https://t.co/hzbV3Cmlyc
bioclinica (Yesterday)
Will you be at CBI's IRT conference in Philly Oct 26-27? https://t.co/C7vuxwnCH7
bioclinica (Yesterday)
Must-see live webinar packed w info for those who want to learn about CV safety from the leading experts.… https://t.co/4y5OaUNeIk
bioclinica (5 days ago)
Right at home near our Princeton offc is where to catch us talking all things #RTSM Oct.18-19.… https://t.co/h1OSFwiSFi
bioclinica (5 days ago)

Latest Blogs: